Unknown

Dataset Information

0

A single intra-articular dose of vitamin D analog calcipotriol alleviates synovitis without adverse effects in rats.


ABSTRACT: 1,25-dihydroxyvitamin-D3 and its derivatives have shown anti-arthritic and chondroprotective effects in experimental animal models with prophylactic dosing. The purpose of this preliminary study was to test the efficacy and safety of calcipotriol, vitamin D analog, as a treatment for a fully-developed knee arthritis in Zymosan-induced arthritis (ZIA) model. Forty 5-month-old male Sprague-Dawley rats were randomized into three arthritis groups and a non-arthritic control group with no injections (10 rats/group). A day after Zymosan (0.1 mg) had been administrated into the right knee joints, the same knees were injected with calcipotriol (0.1 mg/kg), dexamethasone (0.1 mg/kg) or vehicle in a 100 μl volume. The left control knees were injected with saline (PBS) on two consecutive days. All injections, blood sampling and measurements were performed under general anesthesia on days 0, 1, 3 and 8. Internal organs and knees were harvested on day 8 and the histology of the whole knees was assessed blinded. Joints treated with calcipotriol showed a milder histological synovitis than those treated with vehicle (p = 0.041), but there was no statistically significant difference between the dexamethasone and vehicle groups. The clinical severity of arthritis did not differ between the arthritis groups measured by body temperature, swelling of the knee, thermal imaging, clinical scoring or cytokine levels on days 1, 3 and 8. Weight loss was bigger in rats treated with dexamethasone, propably due to loss of appetite,compared to other arthritis groups on days 2-3 (p<0.05). Study drugs did not influence serum calcium ion and glucose levels. Taken together, this preliminary study shows that a single intra-articular injection of calcipotriol reduces histological grade of synovitis a week after the local injection, but dexamethasone did not differ from the vehicle. Calcipotriol may have an early disease-modifying effect in the rat ZIA model without obvious side effects.

SUBMITTER: Huhtakangas JA 

PROVIDER: S-EPMC8057567 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9746120 | biostudies-literature
| S-EPMC7658330 | biostudies-literature
| S-EPMC5551960 | biostudies-other
| S-EPMC6128287 | biostudies-literature
| S-EPMC4402210 | biostudies-literature
| S-EPMC6132473 | biostudies-literature
| S-EPMC8884338 | biostudies-literature
| S-EPMC7000314 | biostudies-literature
| S-EPMC5761897 | biostudies-literature
| S-EPMC5496001 | biostudies-literature